Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus carboplatin/paclitaxel versus carboplatin/paclitaxel in platinum-sensitive advanced serous ovarian cancer
2009-015970-36Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib in ovarian cancer and Serous Papillary Cystadenocarcinoma (2 arms), sponsored by AstraZeneca. Primary endpoint: Percent change in tumor size. Started Sep 2009; status: active.
02
Drugs
olaparib
03
Conditions
ovarian cancerSerous Papillary Cystadenocarcinoma
Beyond the preview
Go deeper on 2009-015970-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015970-36.